Overview
Acuitas Therapeutics specializes in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, including mRNA, siRNA, and DNA payloads. Their clinically validated LNP technology enables approved products like ONPATTRO® for hATTR and COMIRNATY® COVID-19 vaccine, supporting applications in gene editing, RNA interference, and vaccines. The company partners globally with pharma and biotech firms to accelerate drug development without developing proprietary products.
Frequently asked questions
- What LNP delivery capabilities does Acuitas offer?
- Acuitas provides best-in-class LNP systems for nucleic acid therapeutics including mRNA, siRNA, antisense oligonucleotides, and DNA, enabling systemic intravenous delivery for gene editing and modulation, as well as intramuscular vaccine administration.
- What regulatory validations support Acuitas' LNP technology?
- Acuitas' LNP technology is clinically validated in FDA-approved ONPATTRO® (Alnylam) for hATTR amyloidosis and COMIRNATY® (Pfizer-BioNTech) COVID-19 vaccine, with additional programs in clinical development for vaccines and therapeutics.
- What geographies does Acuitas serve and who are key partners?
- Based in Vancouver, Canada, Acuitas partners globally with companies like Bayer for liver-targeted gene editing, Arbor Biotechnologies for rare liver diseases, and Alnylam Pharmaceuticals, supporting international clinical and market advancement.